Stock market analyst Hitesh Chotalia is of the view that investors can hold Ranbaxy Laboratories Ltd stock with target of Rs 560 on crossing its resistance of Rs 492.

According to analyst, the investors can buy the stock with stop loss of Rs 442.

Today, the shares of the company opened at Rs 460 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 538 and a low of Rs 240 on BSE.

Current EPS & P/E ratio stood at 16.19 and 28.51 respectively.

According to fresh reports, Ranbaxy Laboratories new Drug discovery Research (NDDR) has been shifted to Daiichi Sankyo.

Daiichi Sankyo and Ranbaxy declared their plans to amalgamate the New Drug Research and Development System.

The new organization, Daiichi Sankyo Life Science Research Centre in India, based in Gurgoan will play a vital role in the Group's worldwide drug Discovery Research- to generate potential new drugs, particularly in the region of low molecular weight infectious and inflammatory disease cure.

Ranbaxy Lab, in June, introduced a generic version of Prasugrel, prescribed for the treatment of heart trobles, from Daiichi Sankyo group in the country as part of plan to bring drugs from the parent company's stable.